繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Ensysce Biosciences Prices $5 Million Registered Direct Offering

2024-08-29 20:59

08:59 AM EDT, 08/29/2024 (MT Newswires) -- Ensysce Biosciences (ENSC) said Thursday it has entered into agreements for a $5 million registered direct offering involving the sale of about 3.6 million common shares at $0.47 apiece.

The company said it has agreed to exercise warrants issued in February for the purchase of up to roughly 7.2 million shares at a lower price of $0.47 per share versus $1.06 apiece set previously.

In a concurrent private placement, Ensysce will issue unregistered Series A-3 and Series A-4 warrants to purchase up to roughly 14.4 million shares at the same price, the company said, adding that the offering will likely close around Thursday, it added.

Ensysce also said it plans to use the net proceeds to advance its TAAP and MPAR programs and for general working capital, supplementing a recent $14 million NIH grant for its PF614-MPAR program.

The company's shares were down more than 32% in recent Thursday premarket activity.

Price: 0.4200, Change: -0.21, Percent Change: -32.93

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。